SH-1028在EGFR T790M阳性非小细胞肺癌患者中的疗效与安全性:多中心、单臂、开放标签2期试验
该多中心单臂开放标签2期试验纳入286例EGFR T790M阳性晚期非小细胞肺癌患者,口服SH-1028 200 mg/d。A部分客观缓解率55.9%,B部分60.4%;中位无进展生存期分别为12.4个月和12.6个月。SH-1028在二线治疗中有效且可耐受。
要点
- SH-1028 200 mg/d口服用于EGFR T790M阳性晚期NSCLC二线治疗。
- 独立评审委员会评估的客观缓解率A部分55.9%,B部分60.4%。
- 中位无进展生存期A部分12.4个月,B部分12.6个月。
核心结论
- SH-1028在EGFR T790M阳性晚期非小细胞肺癌患者的二线治疗中有效且可耐受。
研究设计与样本
- 多中心、单臂、开放标签2期试验(NCT03823807),共纳入286例EGFR T790M阳性晚期非小细胞肺癌患者,其中A部分59例为剂量验证研究,B部分227例为二线注册研究。
- 患者每日口服SH-1028片200 mg直至疾病进展或不可耐受的毒性,每6周按RECIST 1.1评估肿瘤缓解。
- 主要终点为独立评审委员会评估的客观缓解率,次要终点包括无进展生存期、总生存期、疾病控制率和安全性等。
主要发现
- 截至2021年9月17日数据截止,独立评审委员会评估的客观缓解率A部分为55.9%(95%CI:42.4-68.8),B部分为60.4%(95%CI:53.7-66.8)。
- 中位无进展生存期A部分为12.4个月(95%CI:8.3-20.8),B部分为12.6个月(95%CI:9.7-15.3)。
- 中位总生存期A部分为26.0个月(95%CI:23.3-未达到),B部分总生存期数据不成熟。
- 286例患者中44例发生至少1次3级及以上治疗相关不良事件,最常见为血清肌酸磷酸激酶升高13例(4.5%)、腹泻6例(2.1%)和QT间期延长3例(1.0%)。
- 治疗相关皮疹26例(9.1%),均为1级或2级;研究未报告间质性肺病。
关键数值与推荐
- 客观缓解率A部分55.9%(95%CI:42.4-68.8),B部分60.4%(95%CI:53.7-66.8)。
- 中位无进展生存期A部分12.4个月(95%CI:8.3-20.8),B部分12.6个月(95%CI:9.7-15.3)。
- 中位总生存期A部分26.0个月(95%CI:23.3-未达到),B部分总生存期数据不成熟。
- 3级及以上治疗相关不良事件44例,其中血清肌酸磷酸激酶升高13例(4.5%)、腹泻6例(2.1%)、QT间期延长3例(1.0%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: As a novel third-generation EGFR tyrosine kinase inhibitor (TKI), SH-1028 (formerly oritinib) is developed to inhibit both sensitizing EGFR mutations and EGFR T790M mutation. METHODS: This was a multicenter, single-arm, open-label, phase 2 trial (NCT03823807). Eligible patients were those with advanced NSCLC with centrally confirmed EGFR T790M mutation who progressed after first- or second-generation EGFR TKIs or with primary EGFR T790M mutations. Each patient received SH-1028 tablets orally at 200 mg/d until disease progression or intolerable toxicity. Tumor response was evaluated every 6 weeks per the Response Evaluation Criteria in Solid Tumors, version 1.1. The primary end point was objective response rate by an independent review committee. The secondary end points were progression-free survival, overall survival (OS), disease control rate, safety, and so on. RESULTS: A total of 286 patients with EGFR T790M-positive advanced NSCLC were enrolled in this study, including 59 patients in part A (dose-verification study) and 227 patients in part B (second-line registration study). By data cutoff on September 17, 2021, the independent review committee-assessed objective response rate was 55.9% (95% confidence interval [CI]: 42.4-68.8) in part A and 60.4% (95% CI: 53.7-66.8) in part B. The median progression-free survival was 12.4 months (95% CI: 8.3-20.8) in part A and 12.6 months (95% CI: 9.7-15.3) in part B. The median OS was 26.0 months (95% CI: 23.3-not reached) in part A, and OS was immature in part B. Among the 286 patients, 44 of them experienced at least one grade 3 or higher treatment-related adverse event, with the most common ones as increased serum creatinine phosphokinase level (13 [4.5%]), diarrhea (six [2.1%]), and prolonged QT interval (three [1.0%]). Treatment-related skin rash was reported in 26 patients (9.1%), all grade 1 or 2. There was no interstitial lung disease reported in this study. CONCLUSIONS: SH-1028 is efficacious and tolerable in second-line treatment of patients with advanced NSCLC with positive EGFR T790M.
引用
- Xiong A, Ren S, Liu H, et al. Efficacy and Safety of SH-1028 in Patients With EGFR T790M-Positive NSCLC: A Multicenter, Single-Arm, Open-Label, Phase 2 Trial. J Thorac Oncol. 2022. PMID: 35798241. doi:10.1016/j.jtho.2022.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。